Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's…
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the…
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and…
Company Management Explores Public Listing in the U.S. and Highlights Launch of New Biomarker Tech Integration TAIPEI, Jan. 30, 2026…
Early Investor & Seasoned SaaS Innovator Brings Vast Vertical Expertise, Product Development, & Integration Experience To Advance Luma's Category-Defining AI…
JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on…
Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January…
Wuppertal, Germany, January 29, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that the company will be presenting the results…
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies…